In the drug discovery stage and preclinical trials, scientists can use phenotypic assays to understand how the disease works and its validation and conduct a safety assessment.
Phenotypic assays have a critical part to play in drug discovery. They are crucial tools, and their primary use is to understand disease and its potential translation biomarkers further. They have different endpoints based on the desired outcomes. Assays are used throughout multiple stages of drug research and provide significant advantages to understanding disease biology and developing treatments.
Phenotypic Assays Play in Drug Research & Development (R&D)
In drug research and development, phenotypic screening is a method of phenotypic drug discovery (PDD) conducted to identify molecules that can change a cell’s phenotype and identify leads that produce the desired effect on the body. Animal models and cell-based assays can support this strategy, and one key advantage is that it does not rely on identifying a specific drug target or its role.
Phenotypic Assay Endpoints
The endpoints of phenotypic assays are measurable factors from various systems. These endpoints can include blood pressure, cell cytotoxicity, seizures, and specific biomarkers for factors such as blood cholesterol and glucose. The ability to measure a range of biomarkers is significant for discovering new diseases and developing therapeutic treatments.
Phenotypic Assays in Primary Screening
Scientists conduct primary screening to determine whether microbial species exhibit specific biochemical properties. This screen is carried out as an assay, screen, or other tests on a compound to identify what clinical responses an assay is connected to and which are most valuable.
Phenotypic Assays in Early Discovery Flow Schemes
Flow schemes are necessary for processing screening hits but face many challenges in phenotypic drug discovery. Often, phenotypic assays are used parallel to the primary screening tests to identify relevant targets and a cell-based functional assay. Assays could help develop more efficient, and standardized PDD flow schemes as more information is obtained from them.
Phenotypic Assays in Lead Selection
Phenotypic assays are vital in lead selection during drug research and development (R&D). By measuring various endpoints in a cell-based functional assay, they can identify molecules that change a cell’s phenotype and produce the desired effect on the body. This information helps scientists select the most promising leads for further development as therapeutic treatments.
Synexa Life Sciences
Synexa Life Sciences is determined to bridge the gap between science and life. For 20 years, we have offered analytical and advisory services to a wide client base of mainly Biotech and Pharmaceutical companies to support their clinical development of therapeutics.
Our services focus on biomarker and bioanalytical science and we provide support to clinical programs in areas such as autoimmune, neurology, and oncology. Some of our key services include the following:
- Biomarker Development and Analysis
- Custom Assay Solutions
- Novel Modality Bioanalytics
Contact us today if you would like more information about any of our services.